Nanobiotix Appoints New CFO Amid Late-Stage Clinical Transition
Nanobiotix (NASDAQ: NANO) announced Arnd Christ as new CFO, succeeding a five-year incumbent. The transition coincides with Phase III data readouts and commercial launch preparation for its lead oncology asset.
51CFO view：New CFOs at NASDAQ-listed biotechs must file Form 8-K within 4 business days and immediately master ASC 606 revenue timing, cross-border royalty tax allocations, and FDA-approved inventory capitalization — requiring proven U.S. SOX 302/404 certification experience.
Nanobiotix (NASDAQ: NANO) announced Arnd Christ as new CFO, succeeding a five-year incumbent. The transition coincides with Phase III data readouts and commercial launch preparation for its lead oncology asset.
Source：Google News · CFO 任命